Clinical Trial Goal
To find out:
- The highest dose of ruxolitinib that is safe to give with lenalidomide and methylprednisolone
- If the combination of ruxolitinib, lenalidomide and methylprednisolone is safe and works well to treat multiple myeloma that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years old or older
- Have multiple myeloma that has relapsed or is refractory
- Have had at least 3 different treatments for the myeloma
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Ruxolitinib is a small molecule inhibitor that blocks JAK1 and JAK2 in certain cells.
Lenalidomide is a drug that blocks growth of cancer cells.
You’ll get:
Lenalidomide is a drug that blocks growth of cancer cells.
You’ll get:
- Ruxolitinib – A pill that you take by mouth 2 times each day
- Lenalidomide – A pill that you take by mouth each day for 3 weeks of each month. Depending on when you start the study, you may not get this at first
- Methylprednisolone – A pill that you take by mouth every other day
You’ll continue to get treatment for as long as the clinical trial doctors think it’s best for your health. The doctors will check your health for 4.5 years.
The Food and Drug Administration (FDA) has approved ruxolitinib to treat myelofibrosis. The FDA has approved lenalidomide and methylprednisolone to treat multiple myeloma. Using these drugs together to treat multiple myeloma is new and unproven.
Contacts
James R Berenson, MD, (310)623-1223, jberenson@berensoncancercenter.com
Afra Yehwalashet, ayehu@oncotherapeutics.com
Locations
Sponsors
collaborator: Incyte Corporation, lead: Oncotherapeutics
